Existing backers Lilly Asia Ventures and Osage University Partners helped the UCSF cancer therapy spinout close its series A round.
Fortis Therapeutics, a US-based developer of cancer immunotherapies based on University of California, San Francisco (UCSF) research, completed a $40m series A round on Monday.
The cash came from Lilly Asia Ventures, an investment vehicle for pharmaceutical firm Eli Lilly, as well as spinout-focused venture capital firm Osage University Partners, Avalon Ventures, Bregua Corporation, Vivo Capital, Fulcrum 2020 and Myeloma Investment Fund.
Founded in 2016, Fortis is working on antibody drug conjugates (ADCs) based on technology created by Bin Liu,…
